(2E)-3-(二甲基氨基)-1-(4-氟苯基)丙-2-烯-1-酮 | 138716-20-8

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2E)-3-(二甲基氨基)-1-(4-氟苯基)丙-2-烯-1-酮
• 英文名称: (E)-3-(dimethylamino)-1-(4-fluorophenyl)prop-2-en-1-one
• 英文别名: (E)-1-(4-fluorophenyl)-3-(dimethylamino)prop-2-en-1-one；3-(dimethylamino)-1-(4-fluorophenyl)prop-2-en-1-one；(E)-3-(dimethylamino)-1-(4-fluorophenyl)-2-propen-1-one；(2E)-3-(dimethylamino)-1-(4-fluorophenyl)prop-2-en-1-one
• CAS: 138716-20-8
• 化学式: C₁₁H₁₂FNO
• 分子量: 193.221
• InChiKey: GTJNUCRUOWBWEW-BQYQJAHWSA-N

物化性质

• 熔点：
  94-96 °C(Solv: hexane (110-54-3))
• 沸点：
  271.6±40.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将产品存放在室温、干燥且密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
(2E)-3-(Dimethylamino)-1-(4-fluorophenyl)prop-2-en-1-one
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
(2E)-3-(Dimethylamino)-1-(4-fluorophenyl)prop-2-en-1-one
Ingredient name:
CAS number: 138716-20-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H12FNO
Molecular weight: 193.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (2E)-3-(二甲基氨基)-1-(4-氟苯基)丙-2-烯-1-酮 在 ferrous(II) sulfate heptahydrate 、 硫酸 、 双氧水 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 生成 4-(4-fluorophenyl)pyrimidine-2-carboxamide
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents

  摘要：

  Two series of quinoline derivatives bearing the pyridine/pyrimidine scaffold were synthesized, and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against 5 cancer cell lines (HT-29, H460, MKN-45, A549, and U87MG) were evaluated in vitro. Most compounds showed moderate to excellent potency, and compared to foretinib, the most promising analog 18b (c-Met half-maximal inhibitory concentration [IC50] = 1.39 nM) showed a 7.3-fold increase in activity against HT-29 cell line in vitro. Structure activity relationship studies indicated that regulation of the electron density on the pyridine/pyrimidine ring to a proper degree was a key factor in improving the antitumor activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.08.019
• 作为产物：
  描述：

  4-氟苯乙酮 在 N,N-二甲基甲酰胺二甲基缩醛 作用下， 以 正己烷 为溶剂， 生成 (2E)-3-(二甲基氨基)-1-(4-氟苯基)丙-2-烯-1-酮
  参考文献：
  名称：

  (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and

  摘要：

  这份披露描述了具有抗焦虑活性的取代的1,2,4-三氮唑[1,5-a]嘧啶和取代的1,2,4-三氮唑[4,3-a]嘧啶。

  公开号：

  US04209621A1

文献信息

• 6-N-Linked Heterocycle-Substituted 2,3,4,5-Tetrahydro-1H-Benzo[d]Azepines as 5-Ht2c Receptor Agonists
  申请人：Briner Karin

  公开号：US20080214520A1

  公开（公告）日：2008-09-04

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: Formula (I) where: R 6 is selected from the group consisting of (a, b, c, d, e) and other substituents are as defined in the specification.

  本发明提供了Formula I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环庚烯作为选择性5-HT2C受体激动剂，用于治疗与5-HT2C相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症：Formula (I)其中：R6选自(a、b、c、d、e)等基团组成的群，其他取代基如规范中定义。
• Directed C–C bond cleavage of a cyclopropane intermediate generated from<i>N</i>-tosylhydrazones and stable enaminones: expedient synthesis of functionalized 1,4-ketoaldehydes
  作者：Meiyan Ni、Jianguo Zhang、Xiaoyu Liang、Yaojia Jiang、Teck-Peng Loh

  DOI：10.1039/c7cc07178g

  日期：——

  -quaternary centers via regioseletive C-C bond activation has been described. Through cyclopropanation of bench-stable enaminones with in situ generated diazo reagents from N-tosylhydrazones, followed by selective C-C bond cleavage of the cyclopropane ring affords the 1, 4-ketoaldehyde derivatives in good to excellent yields. This method works with broad substrate scope and high regioseletivity.

  已经描述了一种有效的方法，该方法通过区域选择性CC键活化来构建带有全碳原子的α-季中心的官能化的1，4-酮醛。通过使用原位生成的N-甲苯磺酰hydr酮重氮试剂对稳定的烯胺酮进行环丙烷化，然后选择性地将CC裂解成环丙烷环，可得到1,4-酮醛衍生物，收率好至极佳。该方法适用于较宽的底物范围和较高的重复性。
• Highly Site-Selective Metal-Free C–H Acyloxylation of Stable Enamines
  作者：Fei Wang、Wangbing Sun、Yixin Wang、Yaojia Jiang、Teck-Peng Loh

  DOI：10.1021/acs.orglett.8b00222

  日期：2018.2.16

  A highly site-selective acyloxylation of stable enamines with PhI(OAc)2 under metal-free conditions to afford (E)-vinyl acetate derivatives in good to excellent yields is described. Depending on the judicious choice of the solvent system, either the α- or β-site-selective product could be obtained with high selectivity. For the α-site-selective product, the rearranged amide compound is obtained as

  描述了在无金属条件下用Phi（OAc）2对稳定的烯胺进行高度位点选择性的酰氧基化，从而以良好或优异的收率得到（E）-乙酸乙烯酯衍生物。取决于溶剂系统的明智选择，可以高选择性获得α-位或β-位选择性产物。对于α-位选择产物，获得了重排的酰胺化合物作为主要产物。该反应在温和的反应条件下（室温，无金属和烧瓶）进行，并且具有广泛的底物范围。
• Synthesis of Polyaromatic Rings: Rh(III)-Catalyzed [5 + 1] Annulation of Enaminones with Vinyl Esters through C–H Bond Functionalization
  作者：Gaohui Liang、Jiaxin Rong、Wangbin Sun、Gengjia Chen、Yaojia Jiang、Teck-Peng Loh

  DOI：10.1021/acs.orglett.8b03284

  日期：2018.11.16

  An expedient [5 + 1] annulation method via Rh(III)-catalyzed C–H bond functionalization of enaminones to synthesize polyaromatic rings is described. The reaction tolerates a broad range of functional groups and offers a new entry to construct polycyclic aromatic compounds with amino and formyl substituents. A possible reaction mechanism was proposed based on the results obtained from isotope labeling

  描述了通过Rh（III）催化烯胺酮的C–H键官能化合成聚芳环的简便方法[5 +1]。该反应可耐受各种官能团，并为构建具有氨基和甲酰基取代基的多环芳族化合物提供了新的契机。根据同位素标记实验的结果，提出了可能的反应机理。
• [EN] NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'AGENTS ANTIPALUDIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015028989A1

  公开（公告）日：2015-03-05

  The invention relates to novel heterocyclic compounds of the Formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the Formula I and especially their use as medicaments to treat or prevent malaria infections or to treat or prevent other protozoal diseases like sleeping sickness, Chagas disease, amebiasis, giardiasis, trichomoniasis, toxoplasmosis, and leishmaniasis.

  本发明涉及式I的新颖杂环化合物。本发明还涉及包括制备化合物的方法、包含式I的一个或多个化合物的药物组合物，尤其是它们作为药物用于治疗或预防疟疾感染或治疗或预防其他原虫疾病，如昏睡病、查加斯病、阿米巴病、贾第虫病、滴虫病、弓形虫病和利什曼病。